Drugs / BMS-931699
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04066114 | Dec 2019 → Sep 2023 | disease related to solid organ transplantation | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT02843659 | Oct 2016 → Jul 2017 | Sjogren syndrome | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 2 | NCT02265744 | Nov 2014 → Oct 2017 | lupus erythematosus | Bristol-Myers Squibb | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-931699 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02265744 ↗ |
| Known as | lulizumab pegol | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04066114 ↗ |
| Route | Subcutaneous | “12.5mg subcutaneous (SC) injection Weekly dosing” NCT02265744 ↗ |
| Target | CD28 | “lulizumab pegol and tocilizumab act on specific molecules (specifically CD28 and interleukin 6, respectively)” NCT04066114 ↗ |